Literature DB >> 15148228

Morphallaxia-like ocular histology after intravitreal triamcinolone acetonide.

J B Jonas, U Bleyl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15148228      PMCID： PMC1772159     

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  7 in total

1.  Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone.

Authors:  Matthew S Benz; Timothy G Murray; Sander R Dubovy; Randy S Katz; Charles W G Eifrig
Journal:  Arch Ophthalmol       Date:  2003-02

2.  Pseudo-endophthalmitis after intravitreal injection of triamcinolone.

Authors:  F K P Sutter; M C Gillies
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

3.  Intravitreal triamcinolone and elevated intraocular pressure.

Authors:  R J Wingate; P E Beaumont
Journal:  Aust N Z J Ophthalmol       Date:  1999-12

4.  Exudative macular degeneration and intravitreal triamcinolone. A pilot study.

Authors:  P L Penfold; J F Gyory; A B Hunyor; F A Billson
Journal:  Aust N Z J Ophthalmol       Date:  1995-11

5.  Intravitreal triamcinolone for refractory diabetic macular edema.

Authors:  Adam Martidis; Jay S Duker; Paul B Greenberg; Adam H Rogers; Carmen A Puliafito; Elias Reichel; Caroline Baumal
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  Treatment of intraocular proliferations with intravitreal steroids.

Authors:  R Machemer; G Sugita; Y Tano
Journal:  Trans Am Ophthalmol Soc       Date:  1979

7.  Noninfectious endophthalmitis associated with intravitreal triamcinolone injection.

Authors:  Daniel B Roth; Janet Chieh; Marc J Spirn; Stuart N Green; David L Yarian; Nauman A Chaudhry
Journal:  Arch Ophthalmol       Date:  2003-09
  7 in total
  1 in total

Review 1.  [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].

Authors:  J B Jonas; I Kreissig; B Kamppeter; R F Degenring
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.